QIBA Proton Density Fat Fraction Biomarker Committee (BC) Update Call
Thursday, April 7, 2016 at 3 PM (CDT)

Call Summary

Participants

<table>
<thead>
<tr>
<th>RSNA</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Thomas Chenevert, PhD</td>
<td>Sonja Kinner, MD</td>
</tr>
<tr>
<td>Alexander Guimaraes, MD, PhD</td>
<td>Michael Middleton, MD</td>
<td>Susan Weinmann</td>
</tr>
<tr>
<td>Diego Hernando, PhD</td>
<td>Eric Perlman, MD</td>
<td></td>
</tr>
</tbody>
</table>

Moderator: Dr. Kinner

Update on PDFF BC Discussion with Dr. Jackson/Adding PDFF BC Members

- PDFF BC open to anyone interested
- PDFF BC to have call coordinated by RSNA Staff on a monthly basis; staff to provide call notes
- Small working groups- “Task Forces (TF)”- suggested to address specific topics within the larger Profile
- The PDFF BC was advised to begin with only the BC and add TFs as a specific need for them is identified
- MR Vendor TF can discuss any needs the PDFF BC may have regarding scanner manufacturer input into Claim performance and Profile development
- Statistical support for Claim development will be requested of Dr. Obuchowski
- Dr. Middleton stressed the intense international interest in clinical trial application of PDFF
- Dr. Chenevert, MR Scientific Liaison, introduced himself, described his role and the support he will offer
- PDFF has several advantages that will advance the Profile-writing process, i.e., already a “common” biomarker utilized by many vendor systems

Inclusion Criteria for Potential Meta-Analysis (Dr. Hernando)

- Dr. Hernando’s “Criteria for inclusion of CSE-MRI techniques and studies in meta-analysis” document was distributed by RSNA staff prior to the call
- PDFF BC members were encouraged to review the document and provide feedback
- PDFF BC members were also asked for any advice that would help Dr. Hernando to filter articles obtained during literature search for targeted results
• Dr. Guimaraes mentioned the Round-6 DCE project for which funding was requested for various groundwork studies, e.g., literature search procedures, etc.
• Dr. Guimaraes recommended that Drs. Kinner and Hernando reach out to Drs. Laue and Obuchowski for Claim guidance
• RSNA staff to provide location of Profile template, Profile Stage descriptions, Claims guidance document, etc.: http://qibawiki.rsna.org/index.php/Main_Page.

Current Challenges
• All vendors using PDFF should be engaged/included on the BC
• No data on new applications from Hitachi or Toshiba
• Minimal reproducibility data exists for cross-vendor platform comparisons: literature data does not exist or is not yet published
• All vendors and techniques should be included to show how the same result can be obtained regardless of scanner used

Other Business
• Dr. Hernando has had paper accepted for publication:
  o Topics included the phantom he and colleagues built, shipped to sites to be scanned, and the analysis of resulting data
  o Results were good in that similar data was received from using the same scanning techniques on different platforms
  o PDFF data did not completely match vendor data and there is the need to correct for these differences

Next Call
• Holding a May 5 call could be challenging because of ISMRM; PDFF BC members attending this conference may meet f2f
• Dr. Kinner will be in contact to schedule next call

Next PDFF Biomarker Committee Call: TBD